Firebrick Pharma has published its Phase 2 COVID-19 trial results in the journal Laryngoscope.

The trial achieved its primary endpoint, demonstrating that Nasodine treatment reduced nasal viral load of SARS-CoV-2, leading to 100% clearance of the virus post-treatment.

The company anticipates Nasodine's legal marketing as a nasal antiseptic/disinfectant in multiple international markets, with sales projected to commence in the first half of 2024.

The paper, titled "Impact of 0.5% Povidone-Iodine Nasal Spray (Nasodine) on Shedding of SARS-CoV-2," is available online.